Meda Pharmaceuticals has signed an agreement to acquire ZpearPoint, including global rights to its EB24 product, an over-the-counter treatment for dental erosion.
The EB24 product is based on hydrogen fluoride highly diluted in water. The product has shown in studies that it is able to penetrate enamel surfaces and form calcium fluoride, which results in an antierosive effect. Thus, EB24 works as a protection against dental erosion.
EB24 is expected to be launched in 2015 as a mouth rinse. Patents valid until 2025 have been approved in Europe and are pending in the U.S.
